Repligen (RGEN) Tops Q4 EPS by 16c
Get Alerts RGEN Hot Sheet
Price: $167.60 -1.19%
EPS Growth %: 0.0%
Financial Fact:
Research and development: 1.89M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Research and development: 1.89M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.81, $0.16 better than the analyst estimate of $0.65. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $179.29 million.
GUIDANCE:
Repligen sees FY2022 EPS of $3.21-$3.30, versus the consensus of $3.15. Repligen sees FY2022 revenue of $800-830 million, versus the consensus of $801.46 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Campbell Soup (CPB) Reports In-Line Q4 EPS, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share